Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET
Company Participants
Dave Lennon - President and Chief Executive Officer
Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications
Loretta Itri - Chief Medical Officer
Conference Call Participants
Roger Song - Jefferies
Joseph Catanzaro - Piper Sandler
Tara Bancroft - TD Cowen
Ahu Demir - Ladenburg Thalmann
Operator
Good day and thank you for standing by. Welcome to the Aadi Bioscience First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only-mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
Now I'll turn the call over to Audrey Gross, Head of Corporate Communications for Aadi Bioscience. Ms. Gross, please go ahead.
Unidentified Company Representative
Thank you. Good morning and welcome to the Aadi Bioscience conference call to provide an operational update and review results for the first quarter of 2024. On the call is Dr. Dave Lennon, our President and CEO; Scott Giacobello, our CFO; and our Chief Medical Officer, Dr. Loretta Itri.
Today, we will provide an overview of operational activity and financial results for the first quarter of 2024. We will open the line for questions at the end of the call following closing comments. A quick reminder that statements made on the call today will include forward-looking statements.
Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our annual and quarterly filings with the Securities and Exchange Commission, which can be found at www.sec.gov or on our website at www.aadibio.com.
In addition, any forward-looking statements made on this call represent our views only as of today, May 8th, 2024, and should not be relied upon as representing our view as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.
With that I will turn the call over to Dave for his opening statements. Dave?
Dave Lennon
Good morning, everyone, and thank you for joining us today to review our financial and operational results for the first quarter of 2024.
At Aadi, we're focused on unlocking the full potential of mTOR inhibition by uniquely combining nab technology in the potent mTOR inhibitor, sirolimus. We believe nab-sirolimus has the potential to deliver deeper inhibition of the mTOR pathway and ultimately better outcomes for people living with cancers that are dependent on that pathway.